Review
BibTex RIS Cite

L-karnitin ve kronik myeloid lösemi ilişkisi

Year 2019, Volume: 14 Issue: 53, 34 - 44, 31.03.2019

Abstract

Kronik myeloid lösemi (KML) lösemilerin yaklaşık dörtte birini oluşturur ve her 100.000 kişiden 1 veya 2’sinde bu hastalık görülür. Diyetten elde edilen ya da böbrekte, karaciğere ve beyindeki lizin ve metioninden endojen olarak sentezlenen bir yardımcı faktör olan L-karnitin (LK), uzun zincirli yağlı asitlerini (YA’lar), sitrik asit döngüsü üzerinden ATP üretimi için mitokondriyal matrikse taşır. YA’lerinin blokajına bağlı olan tedavi uygulamaları ve LK seviyelerindeki düşüş, kanser gerilemesine yol açar. Akut miyeloid lösemi (AML) dahil olmak üzere çeşitli kanser tiplerine tek olarak veya kombinasyon halinde LK uygulanması, apoptozun başlatılması yoluyla inhibisyon etkisi gösterir. Bununla birlikte LK üzerine, kansere neden olduğu ve kanser hücrelerini uygulanan kemoterapi ve/veya radyoterapi gibi kanser tedavilerinin verdiği zarardan koruduğu hakkında yayınlanmış bazı tartışmalı çalışmalar da bulunmaktadır. Bu derlemedeki amacımız LK’nın etkilerini genel kanser şeması ile birlikte KML yönünden tekrar değerlendirmekti. Diğer LK baz alınarak yapılan deneysel ve klinik çalışmaların analizleri ve analiz yorumlarına yer verilerek yaptığımız bu derlemenin sonunda, LK’nın gıda takviyesi olarak alınırken veya zayıflamak için kullanılırken veya tek başına ve/veya çoklu kanser tedavilerinde adjuvant terapi ajanı olarak kullanılırken LK’nın plazma konsantrasyon seviyeleri, apoptotik ve anti-apoptotik etkileri ile kanserojen olabilen metabolitleri göz önüne alınarak kanser oluşturma riskine karşı dikkatli olunması gerektiği sonucuna varıldı.

References

  • [1] Chen, Y., Wang, Y., Huang, Y., Zeng, H., Hu, B., Guan, L., Zhang, H., Yu, A.M., Johnson, C.H., Gonzalez, F.J., Huang, M., Bi, H., (2017). PPARα regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase1C. Carcinogenesis, 38(4): 474-483.
  • [2] Deep, G., Schlaepfer, I.R., (2016). Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis. International Journal of Molecular Sciences, 17(7), pii: E1061.
  • [3] Deininger, M.W., Goldman, J.M., Melo, J.V., (2000). The molecular biology of chronic myeloid leukemia. Blood, 96(10): 3343-56.
  • [4] Fan, J.P., Kim, H.S., Han, G.D., (2009). Induction of apoptosis by L-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino Acids, 36(2): 365-72.
  • [5] Huang, H., Liu, N., Yang, C., Liao, S., Guo, H., Zhao, K., Li, X., Liu, S., Guan, L., Liu, C., Xu, L., Zhang, C., Song, W., Li, B., Tang, P., Dou, Q.P., Liu, J., (2012). HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One, 7(12): e52576.
  • [6] Huang, Y., Tan, A., Shen, Y., Lu, J., (1998). Scavenging effect of total flavonoids of lyceum barbarum L on active oxygen radicals and inhibitory effects on heat output from L1210 cells.Wei Sheng Yan Jiu, 27(2): 109-11, 115.
  • [7] Ibrahim A.B., Mansour H.H., Shouman S.A., Eissa A.A., Abu El Nour S.M., (2014). Modulatory effects of L-carnitine on tamoxifen toxicity and oncolytic activity: in vivo study. Human & Experimental Toxicology, 33(9): 968-79.
  • [8] Lee, J.Y., Lee, S.M., Yoon, H.K., Kim, K.H., Choi, M.Y., Lee, W., (2017). A case of synchronous multiple myeloma and chronic myeloid leukemia. Blood Research, 52(3): 219-221.
  • [9] O’Brien, M.E., Borthwick, A., Rigg, A., Leary, A., Assersohn, L., Last, K., Tan, S., Milan, S., Tait, D., Smith, I.E., (2006). Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. British Journal of Cancer, 95(12): 1632-6.
  • [10] Park, S.J., Park, S.H., Kim, J.O., Kim, J.H., Park, S.J., Hwang, J.J., Jin, D.H., Jeong, S.Y., Lee, S..J, Kim, J.C., Kim, I., Cho, D.H., (2001). Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. Biochemical and Biophysical Research Communications, 428(1): 185-90.
  • [11] Pereira, WO, De Carvalho, DD, Zenteno, ME, Ribeiro, BF, Jacysyn, JF, Sardinha, LR, Zanichelli, MA, Hamerschlak, N, Jones, GE, Pagnano, KB, Castro, FA, Calle, Y, Amarante-Mendes, G.P., (2017).BCR-ABL1- induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell Death Disease,8(10): e3114.
  • [12] Pucci, S., Zonetti, M.J., Fisco, T., Polidoro, C., Bocchinfuso, G., Palleschi, A., Novelli, G., Spagnoli, L.G., Mazzarelli, P., (2016).Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer. Oncotarget, 7(15): 19982-96.
  • [13] Qu, Q., Zeng, F., Liu, X., Wang, Q.J., Deng, F., (2016). Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Disease, 19(7): e2226.
  • [14] Rogalidou, M., Evangeliou, A., Stiakaki, E., Giahnakis, E., Kalmanti, M., (2010). Serum carnitine levels in childhood leukemia. Journal of Pediatric Hematology/Oncology, 32(2): e61-9.
  • [15] Roscilli G., Marra E., Mori F., Di Napoli A., Mancini R., Serlupi- Crescenzi O., Virmani A., Aurisicchio L., Ciliberto G., (2013). Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. Journal of Cellular Biochemistry, 114(7): 1665-73.
  • [16] Shao, H., Mohamed, E.M., Xu, G.G., Waters, M., Jing, K., Ma, Y., Zhang, Y., Spiegel, S., Idowu, M.O., Fang, X., (2016). Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget, 7(4): 3832-46.
  • [17] Tas, S., Ozkan, O. F., Cikman, O., Kiraz, A., Akgun, Y., Karaayvaz, M., (2016). L-carnitine has a protective effect on the colonic mucosa during abdominopelvic radiotherapy in rats. Acta Cirurgica Brasileira, 31(9): 615-620.
  • [18] Thomadaki, H., Karaliota, A., Litos, C., Scorilas, A., (2008). Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine Cu2(L-carnitine)2Cl2(H2O)2Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines. Journal of Medicinal Chemistry, 51(13): 3713-9.
  • [19] Weinert, C.H., Empl, M.T., Krüger, R., Frommherz, L., Egert, B., Steinberg, P., Kulling, S.E., (2017). The influence of a chronic L-carnitine administration on the plasma metabolome of male Fischer 344 rats. Molecular Nutrition Food Research, 61(5).
  • [20] Wu, Y., Hurren, R., MacLean, N., Gronda, M., Jitkova, Y., Sukhai, M.A., Minden, M.D., Schimmer, A.D., (2015). Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis, 20(8): 1099-108.
  • [21] Yao, R., Heinrich, M., Weckerle, C.S., (2017). The genus Lycium as food and medicine: A botanical, ethnobotanical and historical review. Journal of Ethnopharmacology, 212: 50-66.
  • [22] Zhang, X.J., Yu, H.Y., Cai, Y.J., Ke, M., (2017). Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway. Oncotarget, 8(4): 5936- 5942.
  • [23] Zhu, B., Zheng, Y.F., Zhang, Y.Y., Cao, Y.S., Zhang, L., Li, X.G., Liu, T., Jiao, Z.Z., Wang, Q., Zhao, Z.G., (2015). Protective effect of L-carnitine in cyclophosphamide-induced germ cell apoptosis. Journal of Zhejiang University Science B, 16(9): 780-7.
Year 2019, Volume: 14 Issue: 53, 34 - 44, 31.03.2019

Abstract

References

  • [1] Chen, Y., Wang, Y., Huang, Y., Zeng, H., Hu, B., Guan, L., Zhang, H., Yu, A.M., Johnson, C.H., Gonzalez, F.J., Huang, M., Bi, H., (2017). PPARα regulates tumor cell proliferation and senescence via a novel target gene carnitine palmitoyltransferase1C. Carcinogenesis, 38(4): 474-483.
  • [2] Deep, G., Schlaepfer, I.R., (2016). Aberrant Lipid Metabolism Promotes Prostate Cancer: Role in Cell Survival under Hypoxia and Extracellular Vesicles Biogenesis. International Journal of Molecular Sciences, 17(7), pii: E1061.
  • [3] Deininger, M.W., Goldman, J.M., Melo, J.V., (2000). The molecular biology of chronic myeloid leukemia. Blood, 96(10): 3343-56.
  • [4] Fan, J.P., Kim, H.S., Han, G.D., (2009). Induction of apoptosis by L-carnitine through regulation of two main pathways in Hepa1c1c 7 cells. Amino Acids, 36(2): 365-72.
  • [5] Huang, H., Liu, N., Yang, C., Liao, S., Guo, H., Zhao, K., Li, X., Liu, S., Guan, L., Liu, C., Xu, L., Zhang, C., Song, W., Li, B., Tang, P., Dou, Q.P., Liu, J., (2012). HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One, 7(12): e52576.
  • [6] Huang, Y., Tan, A., Shen, Y., Lu, J., (1998). Scavenging effect of total flavonoids of lyceum barbarum L on active oxygen radicals and inhibitory effects on heat output from L1210 cells.Wei Sheng Yan Jiu, 27(2): 109-11, 115.
  • [7] Ibrahim A.B., Mansour H.H., Shouman S.A., Eissa A.A., Abu El Nour S.M., (2014). Modulatory effects of L-carnitine on tamoxifen toxicity and oncolytic activity: in vivo study. Human & Experimental Toxicology, 33(9): 968-79.
  • [8] Lee, J.Y., Lee, S.M., Yoon, H.K., Kim, K.H., Choi, M.Y., Lee, W., (2017). A case of synchronous multiple myeloma and chronic myeloid leukemia. Blood Research, 52(3): 219-221.
  • [9] O’Brien, M.E., Borthwick, A., Rigg, A., Leary, A., Assersohn, L., Last, K., Tan, S., Milan, S., Tait, D., Smith, I.E., (2006). Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients. British Journal of Cancer, 95(12): 1632-6.
  • [10] Park, S.J., Park, S.H., Kim, J.O., Kim, J.H., Park, S.J., Hwang, J.J., Jin, D.H., Jeong, S.Y., Lee, S..J, Kim, J.C., Kim, I., Cho, D.H., (2001). Carnitine sensitizes TRAIL-resistant cancer cells to TRAIL-induced apoptotic cell death through the up-regulation of Bax. Biochemical and Biophysical Research Communications, 428(1): 185-90.
  • [11] Pereira, WO, De Carvalho, DD, Zenteno, ME, Ribeiro, BF, Jacysyn, JF, Sardinha, LR, Zanichelli, MA, Hamerschlak, N, Jones, GE, Pagnano, KB, Castro, FA, Calle, Y, Amarante-Mendes, G.P., (2017).BCR-ABL1- induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy. Cell Death Disease,8(10): e3114.
  • [12] Pucci, S., Zonetti, M.J., Fisco, T., Polidoro, C., Bocchinfuso, G., Palleschi, A., Novelli, G., Spagnoli, L.G., Mazzarelli, P., (2016).Carnitine palmitoyl transferase-1A (CPT1A): a new tumor specific target in human breast cancer. Oncotarget, 7(15): 19982-96.
  • [13] Qu, Q., Zeng, F., Liu, X., Wang, Q.J., Deng, F., (2016). Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Disease, 19(7): e2226.
  • [14] Rogalidou, M., Evangeliou, A., Stiakaki, E., Giahnakis, E., Kalmanti, M., (2010). Serum carnitine levels in childhood leukemia. Journal of Pediatric Hematology/Oncology, 32(2): e61-9.
  • [15] Roscilli G., Marra E., Mori F., Di Napoli A., Mancini R., Serlupi- Crescenzi O., Virmani A., Aurisicchio L., Ciliberto G., (2013). Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. Journal of Cellular Biochemistry, 114(7): 1665-73.
  • [16] Shao, H., Mohamed, E.M., Xu, G.G., Waters, M., Jing, K., Ma, Y., Zhang, Y., Spiegel, S., Idowu, M.O., Fang, X., (2016). Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. Oncotarget, 7(4): 3832-46.
  • [17] Tas, S., Ozkan, O. F., Cikman, O., Kiraz, A., Akgun, Y., Karaayvaz, M., (2016). L-carnitine has a protective effect on the colonic mucosa during abdominopelvic radiotherapy in rats. Acta Cirurgica Brasileira, 31(9): 615-620.
  • [18] Thomadaki, H., Karaliota, A., Litos, C., Scorilas, A., (2008). Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine Cu2(L-carnitine)2Cl2(H2O)2Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines. Journal of Medicinal Chemistry, 51(13): 3713-9.
  • [19] Weinert, C.H., Empl, M.T., Krüger, R., Frommherz, L., Egert, B., Steinberg, P., Kulling, S.E., (2017). The influence of a chronic L-carnitine administration on the plasma metabolome of male Fischer 344 rats. Molecular Nutrition Food Research, 61(5).
  • [20] Wu, Y., Hurren, R., MacLean, N., Gronda, M., Jitkova, Y., Sukhai, M.A., Minden, M.D., Schimmer, A.D., (2015). Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells. Apoptosis, 20(8): 1099-108.
  • [21] Yao, R., Heinrich, M., Weckerle, C.S., (2017). The genus Lycium as food and medicine: A botanical, ethnobotanical and historical review. Journal of Ethnopharmacology, 212: 50-66.
  • [22] Zhang, X.J., Yu, H.Y., Cai, Y.J., Ke, M., (2017). Lycium barbarum polysaccharides inhibit proliferation and migration of bladder cancer cell lines BIU87 by suppressing Pi3K/AKT pathway. Oncotarget, 8(4): 5936- 5942.
  • [23] Zhu, B., Zheng, Y.F., Zhang, Y.Y., Cao, Y.S., Zhang, L., Li, X.G., Liu, T., Jiao, Z.Z., Wang, Q., Zhao, Z.G., (2015). Protective effect of L-carnitine in cyclophosphamide-induced germ cell apoptosis. Journal of Zhejiang University Science B, 16(9): 780-7.
There are 23 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Articles
Authors

Haniyeh Behrouzizad This is me

Mine Ergüven

Ayhan Bilir This is me

Publication Date March 31, 2019
Submission Date December 15, 2018
Published in Issue Year 2019 Volume: 14 Issue: 53

Cite

APA Behrouzizad, H., Ergüven, M., & Bilir, A. (2019). L-karnitin ve kronik myeloid lösemi ilişkisi. Anadolu Bil Meslek Yüksekokulu Dergisi, 14(53), 34-44.



All site content, except where otherwise noted, is licensed under a Creative Common Attribution Licence. (CC-BY-NC 4.0)